Nabumetone
Relafen (nabumetone) is a small molecule pharmaceutical. Nabumetone was first approved as Relafen on 1991-12-24. It is used to treat inflammation, osteoarthritis, pain, and rheumatoid arthritis in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nabumetone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RELAFEN | Smithkline Beecham | N-019583 DISCN | 1991-12-24 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nabumetone | ANDA | 2023-06-16 |
| relafen ds | ANDA | 2022-05-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| inflammation | MP_0001845 | D007249 | — |
| osteoarthritis | EFO_0002506 | D010003 | M15-M19 |
| pain | EFO_0003843 | D010146 | R52 |
| rheumatoid arthritis | EFO_0000685 | D001172 | M06.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuralgia | D009437 | EFO_0009430 | — | 1 | 1 | 1 | — | 3 | |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 1 | 1 | — | 2 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | 2 | — | 2 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | 1 | — | 1 |
| Peripheral nervous system diseases | D010523 | G64 | — | — | — | 1 | — | 1 | |
| Antineoplastic combined chemotherapy protocols | D000971 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | 2 | — | — | 2 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 1 | — | — | 2 |
| Weight loss | D015431 | HP_0001824 | — | 2 | 2 | — | — | 2 | |
| Pain | D010146 | EFO_0003843 | R52 | — | 2 | 1 | — | — | 2 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | 1 | — | — | 1 | |
| Non-small-cell lung carcinoma | D002289 | — | 1 | 1 | — | — | 1 | ||
| Cachexia | D002100 | HP_0004326 | R64 | — | 1 | 1 | — | — | 1 |
| Anorexia | D000855 | HP_0002039 | R63.0 | — | 1 | 1 | — | — | 1 |
| Oxidative stress | D018384 | EFO_1001905 | — | 1 | 1 | — | — | 1 | |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 1 | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep initiation and maintenance disorders | D007319 | F51.01 | — | 1 | — | — | 1 | 2 | |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | — | — | 1 | 2 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 2 | 2 | — | — | — | 2 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 1 | — | — | — | 1 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | — | 1 |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | 1 | — | — | — | 1 |
| Cannabis | D002188 | 1 | 1 | — | — | — | 1 | ||
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | 1 | — | — | — | 1 |
| Phantom limb | D010591 | G54.6 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Intellectual disability | D008607 | F73 | 1 | — | — | — | — | 1 | |
| Developmental disabilities | D002658 | EFO_0003852 | F89 | 1 | — | — | — | — | 1 |
| Problem behavior | D000066553 | 1 | — | — | — | — | 1 | ||
| Aggression | D000374 | EFO_0003015 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NABUMETONE |
| INN | nabumetone |
| Description | Nabumetone is a methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, a cyclooxygenase 2 inhibitor and a prodrug. It is a methoxynaphthalene and a methyl ketone. |
| Classification | Small molecule |
| Drug class | cannabinol derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc2cc(CCC(C)=O)ccc2c1 |
Identifiers
| PDB | — |
| CAS-ID | 42924-53-8 |
| RxCUI | 31448 |
| ChEMBL ID | CHEMBL1070 |
| ChEBI ID | 7443 |
| PubChem CID | 4409 |
| DrugBank | DB00461 |
| UNII ID | LW0TIW155Z (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,073 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nabumetone, Relafen ds
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
282 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more